{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:52:13Z","timestamp":1767707533174},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T00:00:00Z","timestamp":1381708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Beta\u2010lactam antibiotics are the mainstay of empiric therapy for febrile neutropenia. Aztreonam may benefit certain patients because of a lack of cross\u2010hypersensitivity to penicillins and cephalosporins. This is the first study, to our knowledge, to evaluate the efficacy of aztreonam as monotherapy for febrile neutropenia (<jats:styled-content style=\"fixed-case\">FN<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our study was a single\u2010center retrospective chart review of patients \u226518\u00a0years of age receiving aztreonam for the treatment of <jats:styled-content style=\"fixed-case\">FN<\/jats:styled-content>. Primary outcome was treatment success of aztreonam monotherapy. Secondary analyses included need for modification to antimicrobial therapy, patients transitioned to aztreonam from another empiric regimen, and patients receiving aztreonam in combination with other antibacterial agents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In patients prescribed aztreonam for first fever, 11 of 27 (40.7%) patients who received aztreonam alone and 19 of 40 (47.5%) given aztreonam plus another antibiotic responded within 96\u00a0h (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.62). Twenty\u2010four (89%) patients prescribed aztreonam monotherapy were alive when <jats:styled-content style=\"fixed-case\">FN<\/jats:styled-content> resolved or treatment ended. Infectious mortality was low (1 patient, 3.7%). In patients prescribed aztreonam monotherapy following an adverse reaction to cefepime, 6 of 11 (54.5%) responded within 96\u00a0h of initiating aztreonam; 10 (91%) were alive when <jats:styled-content style=\"fixed-case\">FN<\/jats:styled-content> resolved or treatment ended.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Aztreonam monotherapy may be acceptable for use in patients with a history of beta\u2010lactam hypersensitivity or following an adverse reaction with another beta\u2010lactam. Further studies are needed to compare efficacy of aztreonam monotherapy with other therapies for the treatment of <jats:styled-content style=\"fixed-case\">FN<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12148","type":"journal-article","created":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T09:12:38Z","timestamp":1381741958000},"page":"145-152","source":"Crossref","is-referenced-by-count":5,"title":["Aztreonam for febrile neutropenia in patients with beta\u2010lactam allergy"],"prefix":"10.1111","volume":"16","author":[{"given":"B.J.","family":"McCullough","sequence":"first","affiliation":[{"name":"Department of Pharmacy Shands Hospital at the University of Florida Gainesville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.E.","family":"Wiggins","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Shands Hospital at the University of Florida Gainesville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Richards","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Shands Hospital at the University of Florida Gainesville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Klinker","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Shands Hospital at the University of Florida Gainesville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.","family":"Hiemenz","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of Florida College of Medicine Gainesville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Wingard","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of Florida College of Medicine Gainesville Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,10,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21847"},{"key":"e_1_2_7_3_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer\u2010Related Infections v.2","author":"National Comprehensive Cancer Network","year":"2009"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90258-5"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1386::AID-CNCR25>3.0.CO;2-X"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.COC.0000020587.73922.89"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.5.951"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.5.1062"},{"key":"e_1_2_7_10_1","volume-title":"Society for Healthcare Epidemiology of America Annual Scientific Meeting; 2011 April 1\u20134; Dallas, TX","author":"Odom RT","year":"2011"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/15.Supplement_1.S206"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198608283150905"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.165"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-10-199405150-00004"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7399.1111"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410017590"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005197.pub3"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12148","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T23:56:34Z","timestamp":1696204594000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,14]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1111\/tid.12148"],"URL":"https:\/\/doi.org\/10.1111\/tid.12148","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,14]]}}}